Curetis
Curetis GmbH is a Germany-based molecular diagnostics company that commercializes the Unyvero Platform, a multiplex PCR and microarray system delivering syndromic pathogen and resistance marker detection in under five hours for hospital and clinical laboratories across 18 countries via distributor partners.
- Company typePrivate
- Founded2007
- HeadquartersHolzgerlingen, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Curetis does
Curetis GmbH is a Germany-based molecular diagnostics company that develops and commercializes the Unyvero Platform for syndromic testing of severe infectious diseases. The platform integrates multiplex PCR amplification with microarray hybridization and melting-curve analysis on single-use application cartridges, enabling simultaneous detection of pathogens and antibiotic resistance markers from native clinical samples in under five hours with approximately two minutes of hands-on time. The product set comprises the Unyvero A50 Analyzer (a two-cartridge random-access processor), the L4 Lysator for sample preparation, the C8 Cockpit for run control and data management, and a menu of application-specific cartridges including panels for bloodstream, respiratory, and implant and tissue infections.
The company's commercial model is a two-stream hardware-plus-consumable setup: one-time placement of the A50 system and recurring sales of single-use application cartridges priced on a quote basis. All sales are executed through third-party distribution rather than direct hospital contracts; A. Menarini Diagnostics entities serve as the exclusive distributor in eight Western European markets (Austria, France, Germany, Greece, Italy, Portugal, Spain, and the UK), supplemented by ten independent regional distributors across Eastern Europe, the Gulf, Egypt, and Latin America, for a stated footprint of 18 countries. Curetis targets hospital and clinical microbiology laboratories seeking faster, more comprehensive alternatives to culture-based diagnostics, particularly for culture-negative infections and antimicrobial resistance guidance.
Curetis was originally incorporated as a Dutch public company and was historically listed on Euronext Amsterdam (ams:CURE). The current operating entity, Curetis GmbH, is registered in Holzgerlingen, Germany, with 51–100 employees and Managing Directors Siew Hwa Ong, PhD and MengHan Kuok, PhD. Cumulative disclosed funding totals approximately $98 million across seven rounds from 2009 to 2019, with the most recent rounds led by Yorkville Advisors and the European Investment Bank. The company and product trademarks are registered in the EU, Switzerland, and the US.
Curetis firmographics
Firmographics- Name
- Curetis
- Legal name
- Curetis GmbH
- Website
- https://curetis.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Curetis GmbH is a Germany-based molecular diagnostics company that commercializes the Unyvero Platform, a multiplex PCR and microarray system delivering syndromic pathogen and resistance marker detection in under five hours for hospital and clinical laboratories across 18 countries via distributor partners.
- Ownership category
- akta.pro rank
Curetis industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
Keywords
Where Curetis is headquartered
LocationHeadquarters
- HQ city
- Holzgerlingen
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Curetis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Unyvero System Hardware: Sale of the Unyvero System hardware including the A50 Analyzer, L4 Lysator, and C8 Cockpit components for molecular diagnostic testing in clinical laboratories.
- Application-Specific Cartridges: Sale of application-specific Unyvero cartridges for different clinical syndromes (e.g., Implant & Tissue Infection panel). Cartridges contain all components required for DNA isolation, amplification, and detection.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Curetis product offering
Product offeringCore offering
Curetis develops and commercializes the Unyvero Platform, a molecular diagnostic system for syndromic testing of severe infectious diseases. The platform uses multiplex PCR and microarray hybridization to simultaneously detect pathogens and antibiotic resistance markers from clinical samples in under 5 hours, and is sold as integrated hardware (A50 Analyzer, L4 Lysator, C8 Cockpit) paired with application-specific cartridges targeting major clinical syndromes such as bloodstream, respiratory, and implant and tissue infections.
Product overview
Curetis offers the Unyvero Platform, a rapid molecular diagnostic system for syndromic testing of severe infections. The platform consists of the Unyvero A50 Analyzer (which processes two cartridges independently with full random-access capabilities), the Unyvero C8 Cockpit (for controlling the system and managing results), and the Unyvero L4 Lysator (for sample preparation). Application-specific Unyvero Cartridges are used with the system to provide simultaneous testing for pathogens and resistance markers across major clinical syndromes, delivering results in under 5 hours with only 2 minutes of hands-on time. The cartridges utilize powerful multiplex PCR technology followed by microarray hybridization for broad panel detection.
Differentiator
Problem solved
Functional benefit
Brands
- Unyvero: Rapid molecular diagnostic solution with broad coverage of pathogens and resistance markers. The Unyvero Platform consists of the Unyvero System and Application-specific Unyvero Cartridges.
Products and services
- Unyvero Platform Rapid molecular diagnostic platform combining the Unyvero System hardware with application-specific cartridges, utilizing multiplex PCR technology to detect microorganisms and antibiotic resistance markers from sample-to-answer in under 5 hours. Intended for hospital and clinical laboratories performing syndromic infectious disease testing.
- Unyvero A50 Analyzer Central processing unit of the Unyvero System that runs two application cartridges independently with full random-access capability, delivering results in less than 5 hours with only 2 minutes of hands-on time. Designed for clinical laboratory use.
- Unyvero L4 Lysator Sample preparation device that lyses a wide variety of clinical samples, including difficult native specimens, preparing them for cartridge-based molecular analysis on the Unyvero System.
- Unyvero C8 Cockpit Control interface of the Unyvero System that manages the testing process, displays results, and supports storage and sharing of diagnostic data from the Unyvero workflow.
- Unyvero Application Cartridge Application-specific disposable cartridges that contain all reagents required for DNA isolation, multiplex PCR amplification, and microarray hybridization detection on the Unyvero System, supporting broad syndromic testing panels for major clinical syndromes.
- Unyvero Implant & Tissue Infection (ITI) Panel Application cartridge panel for the Unyvero System that detects pathogens and antibiotic resistance markers associated with implant and tissue infections, with high specificity in distinguishing between Streptococci and Abiotrophia species.
Quantifiable outcome
- Results delivered in under 5 hours with only 2 minutes hands-on time
- +2 more outcomes
Companies that use Curetis
Customer profileSegments1 record
Ideal customer profiles1 record
Curetis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Curetis partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and regional.
- A. Menarini Diagnostics (Austria)coreA. Menarini GmbH serves as the exclusive distributor for the Unyvero System and cartridges in Austria, operating from Wien.
- A. Menarini Diagnostics (France)coreA. MENARINI Diagnostics France S.A.R.L. distributes Unyvero products in France from their office in Rungis.
- A. Menarini Diagnostics (Germany)coreA. MENARINI DIAGNOSTICS DEUTSCHLAND, a division of BERLIN-CHEMIE AG, distributes Unyvero products in Germany from Berlin.
- A. Menarini Diagnostics (Greece)coreMENARINI diagnostics SA serves as distributor for Unyvero products in Greece, operating from Athens.
- A. Menarini Diagnostics (Italy)coreA.Menarini Diagnostics S.r.L. distributes Unyvero products in Italy from their operative offices in Bagno a Ripoli (Florence).
- A. Menarini Diagnostics (Portugal)coreMenarini Diagnósticos, Lda distributes Unyvero products in Portugal from Paço de Arcos.
- A. Menarini Diagnostics (Spain)coreA.Menarini Diagnostics distributes Unyvero products in Spain from Badalona near Barcelona.
- A. Menarini Diagnostics (United Kingdom)coreA.Menarini Diagnostics Ltd. distributes Unyvero products in the UK from Winnersh-Wokingham.
- ANNAR Health Technologies (Colombia)regionalAnnar Diagnóstica Import SAS distributes Unyvero products in Colombia from Bogotá.
- Quantum Eesti AS (Estonia)regionalQuantum Eesti AS distributes Unyvero products in Estonia from Räni, near Tartu.
- Eruditio - Sensuum sprl (Belgium, Netherlands, Luxembourg)regionalEruditio - Sensuum sprl distributes Unyvero products in Belgium, Netherlands, and Luxembourg from Waterloo, Belgium.
- Future Horizon Scientific (Egypt)regionalFuture Horizon Scientific distributes Unyvero products in Egypt from Cairo.
- KEIS (Kosovo)regionalKEIS (Kosova Export Import Supply Pharmaceutical) Sh.P.K. distributes Unyvero products in Kosovo from Prishtine.
- Advanced Technology Company (Kuwait)regionalAdvanced Technology Company distributes Unyvero products in Kuwait from Hawalli.
- Biomedical Innovations Limited Co. (Saudi Arabia)regionalBiomedical Innovations Limited Co. distributes Unyvero products in Saudi Arabia from Riyadh.
- NoaTech UAB (Lithuania, Latvia)regionalNoaTech UAB distributes Unyvero products in Lithuania and Latvia from Druskininkai, Lithuania.
- Synttergy Consult (Romania)regionalSynttergy Consult distributes Unyvero products in Romania from Bucharest.
- AKOMED d.o.o. (Serbia, North Macedonia, Bosnia Hercegovina, Montenegro, Croatia)regionalAKOMED d.o.o. distributes Unyvero products across multiple Balkan countries including Serbia, North Macedonia, Bosnia Hercegovina, Montenegro, and Croatia from Belgrade.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Curetis competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Curetis social profiles
Digital presenceCuretis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curetis leadership team
Management profileNumber of profiles
Profiles5 records
Curetis funding detail
Funding detailFunding overview
Funding rounds7 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curetis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curetis
What does Curetis do?
Curetis develops and commercializes the Unyvero Platform, a molecular diagnostic system for syndromic testing of severe infectious diseases. The platform uses multiplex PCR and microarray hybridization to simultaneously detect pathogens and antibiotic resistance markers from clinical samples in under 5 hours, and is sold as integrated hardware (A50 Analyzer, L4 Lysator, C8 Cockpit) paired with application-specific cartridges targeting major clinical syndromes such as bloodstream, respiratory, and implant and tissue infections.
Is Curetis a public or private company?
Curetis is a private company. It is classified as unknown and is currently operating.
When was Curetis founded?
Curetis was founded in 2007. It employs 51 to 100 people.
Where is Curetis based?
Curetis is headquartered in Holzgerlingen, Germany, in the Europe region.
How does Curetis make money?
Two revenue lines are on record. Unyvero System Hardware is the primary driver. The others are application-Specific Cartridges.
Does Curetis have an API?
No public API is recorded for Curetis.
What industry is Curetis in?
Curetis's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAD, Hematology POCT (CBC/hemoglobin/hematocrit), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.